Загрузка...
On the Regulatory Approval Pathway of Biosimilar Products
Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA has taken the lead in the regulatory approval fram...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3763644/ https://ncbi.nlm.nih.gov/pubmed/24281406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph5040353 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|